Complete Men's Health Panel
A broad men's health panel: hormones, heart, metabolic, and organ function in one blood draw.
Lp(a), in full lipoprotein(a), is a cholesterol-carrying particle in the blood made of an LDL particle with the protein apolipoprotein(a) attached. According to the European Atherosclerosis Society (EAS), mainly the liver and, to a small extent, the kidneys clear Lp(a).
A high Lp(a) is a cause of cardiovascular disease and of narrowing of the aortic valve according to the EAS; the aortic valve is the valve through which the heart pumps blood into the main artery. Only a blood test measures how high Lp(a) is.
The EAS expresses Lp(a) in nanomoles per litre, among other units, and proposes that guidelines consider a grey zone, for example 75 to 125 nmol/L, with a value below that zone that would rule out the risk and a value from 125 nmol/L that would rule it in.
Doctor's Assessment Included
Lp(a) is a fat particle whose level is largely inherited. Laboratories report it in nmol/l or mg/l, so a result can only be compared with the limit of the laboratory that measured it.
| Result | Value (g/l) |
|---|---|
| Normal | < 0,3 |
| Borderline | 0,3–0,5 |
| Elevated | ≥ 0,5 |
Lp(a) is largely inherited and stays almost constant throughout life. The risk rises gradually with the value; the EAS stresses that there is no biological threshold. The NHG guideline CVRM uses > 50 mg/dl (0.50 g/l, 80th percentile) as the cut-off and advises against screening the general population. Some laboratories apply a stricter upper limit (0.3 g/l), which matches the lower end of the EAS grey zone.
Source: Nederlands Huisartsen Genootschap Reference population: Adults (NHG guideline CVRM; EAS 2022)
Source: European Atherosclerosis Society Reference population: Adults (NHG guideline CVRM; EAS 2022)
Reference ranges may vary between laboratories. When you order a test, a BIG-registered doctor assesses your personal results in context. For treatment decisions, discuss your results with your GP.
The upper limit runs from 60 nmol/l at Unilabs to 75 nmol/l at Star-shl.
| Laboratory | Group | Reference value (nmol/l) | Relative scale |
|---|---|---|---|
| Star-shl | · Everyone · a limit, not a range | < 75 nmol/l |
75
|
| Unilabs | · Everyone · a limit, not a range | < 60 nmol/l |
60
|
| Unilabs | · Everyone · grey zone for cardiovascular disease | 75–125 nmol/l |
75 125
|
| Unilabs | · Everyone · a limit, not a range · raised risk of cardiovascular disease | > 125 nmol/l |
125
|
| Certe | · Everyone · 18 years and older · a limit, not a range | < 500 mg/L mg/L | |
| Certe | · Everyone · grey zone | 300–500 mg/L mg/L | |
| Certe | · Everyone · a limit, not a range · high risk | > 500 mg/L mg/L | |
| Diagnostiek voor U | · Everyone · a limit, not a range | < 75 nmol/L |
75
|
Source: Star-shl
Source: Unilabs
Source: Certe
Source: Diagnostiek voor U
Each value as the laboratory itself publishes it, retrieved in 2026.
The Lp(a) test measures lipoprotein(a) in serum; Star-SHL uses immunoturbidimetry, names AML as its source and gives < 75 nmol/l as the reference value. According to the EAS, Lp(a) usually reaches adult levels by around age five, but the value can still rise until adulthood.
The LPA gene, which largely sets the level of Lp(a), has been established since 2013 as a major contributor to the risk of narrowing of the aortic valve, according to the EAS. A high Lp(a) goes together with calcification of that valve according to the EAS, especially in relatively young, healthy people aged 45 to 54.
The EAS advises an Lp(a) measurement at least once in adults, while the Dutch guideline on inherited dyslipidaemia sees no justification for screening the general population and considers a measurement for, among others, people with more than a 5% chance of dying from cardiovascular disease within ten years according to the SCORE table.
An Lp(a) below 60 nmol/l falls within the reference value at Unilabs; Unilabs gives no lower limit. In men, Lp(a) stays relatively constant according to the EAS, and castration, surgical or with medicines, raises the value slightly according to the EAS.
A high Lp(a) goes together with a higher absolute and relative risk of narrowing of the aortic valve, ischaemic stroke, heart attack and heart failure according to the EAS. For thrombosis in the veins, the evidence in the EAS consensus does not demonstrate a causal link.
Reduced liver function
Lp(a) is made in the liver, so a poorly working liver can lower the level.
Overactive thyroid
An overactive thyroid can lower Lp(a); after treatment the level rises by 20 to 25 percent.
Hormone therapy after menopause
Hormone replacement therapy after menopause lowers Lp(a) by about 25 percent.
Severe acute illness
In life-threatening conditions such as sepsis or severe burns, Lp(a) is lower.
Inherited level
The Lp(a) level is thought to be mainly set by the genes and to barely change from adulthood.
Kidney disease
Reduced kidney function can raise Lp(a), and in nephrotic syndrome the level is 3 to 5 times higher.
Pregnancy
Lp(a) can double during pregnancy.
Underactive thyroid
An underactive thyroid can raise Lp(a); treatment lowers it by 5 to 20 percent.
With a very high Lp(a) and progressing cardiovascular disease despite optimal treatment of the other risk factors, lipoprotein apheresis can be considered according to the EAS, a treatment that filters Lp(a) out of the blood, as uncontrolled data indicate benefit. Pelacarsen, a new medicine that blocks the production of apo(a) in the liver, gave mean falls in Lp(a) of 80 and 72% in early studies according to the EAS, depending on the dosing.
The Dutch guideline on inherited dyslipidaemia gives no exact figure for the risk of cardiovascular disease with a high Lp(a): because quantitative data were lacking, it could draw no conclusion about the ten-year or lifetime risk. The EAS describes the risk as rising gradually with the value, already below the usual limits.
Nicotinic acid is not recommended by the EAS for a high Lp(a), because two outcome studies showed no clinical benefit. According to the Dutch guideline on inherited dyslipidaemia, nicotinic acid did lower Lp(a) in earlier studies, without that leading to less cardiovascular disease.
Whether aspirin helps with a markedly raised Lp(a) is uncertain according to the EAS, and current data do not support basing aspirin use on the Lp(a) value.
These panels measure values from the same category as this marker.
A broad men's health panel: hormones, heart, metabolic, and organ function in one blood draw.
Advanced heart health panel with hs-CRP and homocysteine.
Blood sugar, insulin resistance, lipids, and liver markers.
Age-appropriate screening including testosterone and PSA.
Medical reviewer
Dr. Naimi oversees the medical standards behind our content and assessments.
Medical policyDoctor's Assessment Included
Every result includes a professional assessment from a BIG-registered doctor. For treatment decisions, discuss your results with your GP.
Lipoprotein(a)
€36,-
We use cookies to analyze site usage and measure ad effectiveness. Privacy Policy